ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vaccine + Immune Checkpoint Blockade as Maintenance for Newly Diagnosed mCRC

147 views
June 13, 2022
0 Comments
Login to view comments. Click here to Login